The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
about
Mechanism of action of lenalidomide in hematological malignanciesBiological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaImmunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisA phthalimide derivative that inhibits centrosomal clustering is effective on multiple myelomaLong-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.Amyloidosis and POEMS syndrome.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Kidney dysfunction during lenalidomide treatment for AL amyloidosis.Amyloidosis: pathogenesis and new therapeutic options.Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract.Thyroid dysfunction from antineoplastic agents.Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ InvolvementActivity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Pharmacokinetics and tissue disposition of lenalidomide in mice.The amyloidoses: clinical features, diagnosis and treatment.Al amyloidosisThe evolving role of lenalidomide in the treatment of hematologic malignancies.Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trialA phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugsA Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules.Perspectives in treatment of AL amyloidosis.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Splenic plasma cells can serve as a source of amyloidogenic light chainsTreatment of plasma cell dyscrasias with lenalidomide.Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chainCurrent trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.Lenalidomide: a synthetic compound with an evolving role in cancer management.Light chain amyloidosis: a case presentation and review.Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management.
P2860
Q21198872-E31731DA-5596-4C3B-B3D9-707995940D57Q21285161-F6AB73EB-5D97-48EB-9619-375278BD8833Q26827340-64EE0973-1820-4B93-8969-D9A298B2E913Q26829735-5CFF0218-AF61-4E44-93FE-089E0A640A47Q28480621-50F0F314-D1B1-4543-AD45-F4EF650A48FBQ33292965-DFC1A23A-9051-4B28-B149-7F67ABDD1CBBQ33304297-2AC73946-9A67-4069-8903-2DDA693EEBF3Q33427726-FB9323DE-771E-4D76-82C7-C5D7A31110E9Q33802749-330B6DB9-56C0-450D-AE4A-F21F73107871Q33867198-6481E064-01B2-4C68-A94C-3DF0884086E7Q34253548-4FC4FF5D-C900-4A2B-93BF-7D94A5AAA6D6Q34448455-58078078-36BA-4967-A238-111CCF24FBB8Q34450910-577C7849-2A92-4939-99E1-5F62FAE3D1D4Q35025410-921F2829-E40E-49AE-8BC2-261173EE5934Q35111771-DBDB3B20-86BB-42B4-BFAA-53EE7683E99BQ35208216-4333CA16-E236-4EFA-A395-DC5230F79AD8Q35500038-B48C4C3E-2C03-4749-A184-31EE0F5BB26FQ36009723-639B494A-6A0B-4A58-B584-6AE3DC2999C9Q36015183-64B52A25-9273-475E-95CB-519EFD8E7324Q36163205-153D6CC9-95D9-4294-8627-B939FAE2029CQ36331493-00E43446-A336-4C53-8784-033F2B501AD7Q36366997-CCED6C62-069C-4944-9FBF-E5A31571BBB0Q36392233-7572A7D9-EF95-4A1E-A52F-F7BB12CCE9EBQ36739807-2F5F8476-94F8-43B7-AA5F-FF103BA96940Q36805878-C501952D-4EA1-42E4-B39F-CD3E36E2AEB8Q36862339-49FDC4B5-768D-4347-A5C4-4D8388ED3660Q36910372-349980AB-6B7B-4B12-B2B9-42CDCBBC1E8CQ36950813-DE5A92F2-3824-4B67-9FAC-D52D0E8C4D93Q36960501-612DC82D-2A79-4D4B-9D59-208C82322D86Q37045885-EA733272-9EC3-4A05-86A6-DC2A314AB05DQ37045900-C25A322A-0F8D-4087-8933-D68C56AB9B3CQ37100733-1E320839-57F9-469D-B722-654A4945F062Q37176044-FB2C2914-A656-4D51-9AA2-1D9DFCC414DBQ37212712-0EC8E1A5-2C9D-4F58-881E-121D81937B59Q37284404-27344EB8-D614-41FE-ABFD-9AACAE9E735DQ37370051-719C6CDB-87EF-45CE-AE37-74AD9E38CE45Q37624857-FA115FA1-4B75-4AAC-A730-80D7EB10B925Q37791617-C7838A54-E165-4963-A339-1EC6A2AB81FFQ37829345-01A2FB2E-A196-4EC3-9DAF-49080D7C39D7Q37832199-B1948C83-F573-46B1-A67B-4CD32AA66C7D
P2860
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The activity of lenalidomide w ...... primary systemic amyloidosis.
@ast
The activity of lenalidomide w ...... primary systemic amyloidosis.
@en
type
label
The activity of lenalidomide w ...... primary systemic amyloidosis.
@ast
The activity of lenalidomide w ...... primary systemic amyloidosis.
@en
prefLabel
The activity of lenalidomide w ...... primary systemic amyloidosis.
@ast
The activity of lenalidomide w ...... primary systemic amyloidosis.
@en
P2093
P50
P1433
P1476
The activity of lenalidomide w ...... primary systemic amyloidosis.
@en
P2093
Brian Kabat
Jacob B Allred
John A Lust
Philip R Greipp
Shaji K Kumar
Susan M Geyer
Thomas E Witzig
P304
P356
10.1182/BLOOD-2006-07-032987
P407
P50
P577
2006-09-28T00:00:00Z